Neuroinflammation is a common pathological feature of many neurodegenerative diseases,
including amyotrophic lateral sclerosis (ALS), and is characterised by activated CNS …

Amyotrophic lateral sclerosis (ALS) is a debilitating and rapidly fatal neurodegenerative
disease. Despite decades of research and many new insights into disease biology over the …

Mesenchymal stromal cells (MSCs) exert broad immunosuppressive potential, modulating
the activity of cells of innate and adaptive immune systems. As MSCs become accepted as a …

Stem cell therapy is an emerging alternative therapeutic or disease-modifying strategy for
amyotrophic lateral sclerosis (ALS). The aim of this open-label phase I clinical trial was to …

Neuroinflammation is involved in the pathogenesis of amyotrophic lateral sclerosis (ALS),
but only limited data are available on systematic peripheral and central immune cell profiles …

Mesenchymal stromal cells (MSCs) are the subject of numerous clinical trials, largely due to
their immunomodulatory and tissue regenerative properties. Toll-like receptors (TLRs) …

Objective To assess the safety and efficacy of 2 repeated intrathecal injections of autologous
bone marrow–derived mesenchymal stem cells (BM‐MSCs) in amyotrophic lateral sclerosis …

The regulation of microglial cell phenotype is a potential therapeutic intervention in
neurodegenerative disease. Previously, we reported that transforming growth factor-β (TGF …

Mesenchymal stem cells (MSCs) show immunoregulatory properties. Here, we compared
MSCs obtained from placenta (P-MSCs) and umbilical cord (C-MSCs) from the same donor …

Neurological dysfunction and motor neuron degeneration in amyotrophic lateral sclerosis
(ALS) is strongly associated with neuroinflammation reflected by activated microglia and …